AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 358727 — intervention group
Group type: COMPARATOR
Intervention: No paracervical blocks administered to saline-treated patients
Number of subjects: 100
Study 358727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative abortion rates of PGF2alpha-treated patients with paracervical blocks
Number of subjects: 100
Study 358727 — intervention group
Group type: COMPARATOR
Intervention: Cumulative abortion rates of PGF2alpha-treated patients without paracervical blocks
Number of subjects: 100
Study 358727 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete abortion rates of PGF2alpha-treated patients with paracervical blocks
Number of subjects: 100
Study 358727 — intervention group
Group type: COMPARATOR
Intervention: Incomplete abortion rates of PGF2alpha-treated patients without paracervical blocks
Number of subjects: 100
Study 31339827 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard adjuvant chemotherapy (physician's choice of either cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide and doxorubicin)
Number of subjects: 633
Study 31339827 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 633
Study 31339827 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard adjuvant chemotherapy
Number of subjects: 633
Study 28552811 — intervention group
Group type: EXPERIMENTAL
Intervention: Transumbilical incision (TUI)
Number of subjects: 50
Study 28552811 — intervention group
Group type: COMPARATOR
Intervention: Periumbilical incision (PUI)
Number of subjects: 50
Study 28552811 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants valuing appearance of umbilicus
Number of subjects: 50
Study 28552811 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher preoperative CSS
Number of subjects: 50
Study 26028929 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin treatment for 4 weeks (n = 36)
Number of subjects: 102
Study 26028929 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin treatment for 8 weeks (n = 43)
Number of subjects: 102
Study 26028929 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin treatment for 12 weeks (n = 23)
Number of subjects: 102
Study 26028929 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin treatment for 4 weeks vs 12 weeks
Number of subjects: 102
Study 26028929 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin treatment for all periods
Number of subjects: 102
Study 23818710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment strategies (tight control)
Number of subjects: 0
Study 23818710 — intervention group
Group type: COMPARATOR
Intervention: Less intensive treatment strategies
Number of subjects: 0
Study 21634248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecysto‐cholangiography (CCC)
Number of subjects: 60
Study 21634248 — intervention group
Group type: COMPARATOR
Intervention: Transcystic‐cholangiography
Number of subjects: 60
Study 18942777 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment for rheumatoid arthritis
Number of subjects: 0
Study 18942777 — intervention group
Group type: COMPARATOR
Intervention: Existing treatments
Number of subjects: 0
Study 16963040 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: recombinant hFSH from day 3 until follicles reached 13‐14 mm, then lowered to 75 IU daily, with daily injections of 200 IU of hCG and a GnRH antagonist until final maturation
Number of subjects: 323
Study 16963040 — intervention group
Group type: COMPARATOR
Intervention: Group B: recombinant hFSH and a GnRH antagonist
Number of subjects: 323
Study 16963040 — intervention group
Group type: COMPARATOR
Intervention: Group C: recombinant hFSH and a GnRH agonist
Number of subjects: 323
Study 16963040 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 323
Study 14599958 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C-Hiolein diet
Number of subjects: 24
Study 14599958 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme supplementation therapy
Number of subjects: 24
Study 11073329 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified tooth stain index
Number of subjects: 182
Study 11073329 — intervention group
Group type: COMPARATOR
Intervention: Smoking and tea-drinking
Number of subjects: 182
Study 8761937 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal shiftwork (four on, three off)
Number of subjects: 23
Study 8761937 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal shiftwork (eight on, seven off)
Number of subjects: 23
Study 8761937 — intervention group
Group type: COMPARATOR
Intervention: Diurnal living patterns
Number of subjects: 23
Study 1533455 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 25 mg/kg/day divided into two doses for 3 months
Number of subjects: 60
Study 1533455 — intervention group
Group type: COMPARATOR
Intervention: Glycoproteins from Klebsiella pneumoniae (GKP) 2 tablets per day during 8 days in the 1st month and 1 tablet per day during 8 days in the following 2 months
Number of subjects: 60
Study 3889259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal administration of human surfactant
Number of subjects: 45
Study 3889259 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with intermittent mandatory ventilation
Number of subjects: 45
Study 31557127 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral aromatase inhibitors (AIs)
Number of subjects: 76
Study 31557127 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous daily growth hormone (GH)
Number of subjects: 76
Study 31557127 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (AI/GH)
Number of subjects: 76
Study 31557127 — intervention group
Group type: EXPERIMENTAL
Intervention: QoLISSY questionnaire
Number of subjects: 76
Study 31557127 — intervention group
Group type: EXPERIMENTAL
Intervention: KIDSCREEN questionnaire
Number of subjects: 76
Study 30914176 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling + app group (IG)
Number of subjects: 833
Study 30914176 — intervention group
Group type: COMPARATOR
Intervention: Counseling only group (CG)
Number of subjects: 833
Study 27714970 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed cow's milk protein formula
Number of subjects: 0
Study 27714970 — intervention group
Group type: COMPARATOR
Intervention: Intact cow's milk protein formula
Number of subjects: 0
Study 27714970 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal T1D status
Number of subjects: 0
Study 27714970 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional feeding patterns
Number of subjects: 0
Study 26259133 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (HC) meal
Number of subjects: 28
Study 26259133 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fat (HF) meal
Number of subjects: 28
Study 26259133 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy
Number of subjects: 28
Study 26259133 — intervention group
Group type: COMPARATOR
Intervention: Control (OC) group with HC and HF meals
Number of subjects: 28
Study 23447647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive room heating (mean temperature 24.2 ± 1.7°C)
Number of subjects: 146
Study 23447647 — intervention group
Group type: COMPARATOR
Intervention: Weak room heating (mean temperature 13.9 ± 3.3°C)
Number of subjects: 146
Study 23447647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive room heating
Number of subjects: 146
Study 21669585 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid fish oil (2x10%, 40%, and 100%)
Number of subjects: 100
Study 21669585 — intervention group
Group type: COMPARATOR
Intervention: 100% extra light olive oil
Number of subjects: 100
Study 19564806 — intervention group
Group type: EXPERIMENTAL
Intervention: Above-elbow posterior fiberglass slab
Number of subjects: 50
Study 19564806 — intervention group
Group type: COMPARATOR
Intervention: Collar and cuff immobilization
Number of subjects: 50
Study 16125357 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week smoking cessation program plus Internet-assisted instruction (IAI) program
Number of subjects: 77
Study 16125357 — intervention group
Group type: COMPARATOR
Intervention: No intervention (comparison group)
Number of subjects: 77
Study 15517622 — intervention group
Group type: EXPERIMENTAL
Intervention: Willow bark extract (240 mg salicin/day)
Number of subjects: 153
Study 15517622 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (100 mg/day)
Number of subjects: 153
Study 15517622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 11709562 — intervention group
Group type: EXPERIMENTAL
Intervention: FC/FO (5‐FU/folinic acid combined with alternating irinotecan and oxaliplatin)
Number of subjects: 62
Study 11709562 — intervention group
Group type: COMPARATOR
Intervention: OC (oxaliplatin and irinotecan)
Number of subjects: 62
Study 9146769 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole plus amoxycillin
Number of subjects: 287
Study 9146769 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole plus clarithromycin
Number of subjects: 287
Study 8198064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (500 mg, three times a day) for 5 of the 10 weeks
Number of subjects: 25
Study 8198064 — intervention group
Group type: COMPARATOR
Intervention: Typical Western diet
Number of subjects: 25
Study 8198064 — intervention group
Group type: COMPARATOR
Intervention: Diet with predicted poorly bioavailable iron
Number of subjects: 25
Study 3281542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation tubes (grommets)
Number of subjects: 115
Study 3281542 — intervention group
Group type: COMPARATOR
Intervention: Control group without ventilation tubes
Number of subjects: 115
Study 29982870 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy (HAIC)
Number of subjects: 58
Study 29982870 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 58
Study 26544615 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based decision support for depression treatment
Number of subjects: 289
Study 24213308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CPH)
Number of subjects: 38
Study 24213308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA)
Number of subjects: 38
Study 23989915 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) 2-3 mg/kg per day
Number of subjects: 72
Study 23989915 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine 3.2 g per day
Number of subjects: 72
Study 21256483 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomy with barrier
Number of subjects: 694
Study 21256483 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy without barrier
Number of subjects: 694
Study 21256483 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy with barrier
Number of subjects: 694
Study 21256483 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy without barrier
Number of subjects: 694
Study 19270470 — intervention group
Group type: EXPERIMENTAL
Intervention: Day clinic treatment
Number of subjects: 55
Study 19270470 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 55
Study 16549463 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA-diet rich in CLA (4.7 g/d of c9,t11- and t10,c12-CLA isomers in equal amounts)
Number of subjects: 60
Study 16549463 — intervention group
Group type: EXPERIMENTAL
Intervention: VA-diet rich in VA (3.6 g/d)
Number of subjects: 60
Study 16549463 — intervention group
Group type: COMPARATOR
Intervention: C-diet, a control diet with a low content of VA and CLA
Number of subjects: 60
Study 14703736 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol supplementation (500 IU/day)
Number of subjects: 104
Study 14703736 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 104
Study 11070960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane in Air:O2
Number of subjects: 920
Study 11070960 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane in N2O:O2
Number of subjects: 920
Study 9057190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatin (Creon) supplementation
Number of subjects: 11
Study 9057190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8420411 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (25 U/kg) administered intravenously 10 min before challenge
Number of subjects: 25
Study 8420411 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized heparin (20,000 units) administered 10 min before challenge
Number of subjects: 25
Study 3310589 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine HCl therapy
Number of subjects: 81
Study 29862568 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention therapy combined with routine medications
Number of subjects: 156
Study 29862568 — intervention group
Group type: COMPARATOR
Intervention: Routine medication
Number of subjects: 156
Study 26585394 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔMTTp3-6 (perfusion change between 3 and 6 hours)
Number of subjects: 0
Study 26585394 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔMTT6-24 (perfusion change between 6 and 24 hours)
Number of subjects: 0
Study 24921074 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone diary
Number of subjects: 47
Study 24921074 — intervention group
Group type: COMPARATOR
Intervention: Paper diary
Number of subjects: 47
Study 24378099 — intervention group
Group type: EXPERIMENTAL
Intervention: CIK cells transfusion
Number of subjects: 128
Study 24378099 — intervention group
Group type: COMPARATOR
Intervention: Regular follow-up
Number of subjects: 128
Study 15729225 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg orally
Number of subjects: 130
Study 15729225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 12893326 — intervention group
Group type: EXPERIMENTAL
Intervention: OXY‐TDS 3.9 mg/day
Number of subjects: 361
Study 12893326 — intervention group
Group type: EXPERIMENTAL
Intervention: TOL‐LA 4 mg/day
Number of subjects: 361
Study 12893326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study 9467472 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam FDDF (40 mg sublingual)
Number of subjects: 80
Study 9467472 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (75 mg intramuscular)
Number of subjects: 80
Study 9467472 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam FDDF
Number of subjects: 80
Study 9467472 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium
Number of subjects: 80
Study 7874912 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical care medicine elective consisting of orientation, interactive conferences, technical skills laboratories, daily rounds, and patient-care experience.
Number of subjects: 0
Study 2089356 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (2 x 200 mg/day for 6 weeks)
Number of subjects: 12
Study 2089356 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6-week period)
Number of subjects: 12
Study 512665 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 9
Study 512665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 9
Study 512665 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 9
Study 512665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30755066 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP Dating Violence intervention
Number of subjects: 317
Study 30755066 — intervention group
Group type: COMPARATOR
Intervention: Website containing information about dating violence
Number of subjects: 317
Study 30755066 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 317
Study 30219027 — intervention group
Group type: COMPARATOR
Intervention: Scalp nerves block with 15 ml bupivacaine 0.5%, 15 ml lidocaine 2%, in 1:400000 epinephrine (Group LA)
Number of subjects: 64
Study 30219027 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp nerves block with 15 ml bupivacaine 0.5%, 15 ml lidocaine 2%, in 1:400000 epinephrine plus 15 IU/ml Hyaluronidase (Group H)
Number of subjects: 64
Study 27308644 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy (esomeprazole 20 mg, twice daily)
Number of subjects: 145
Study 27308644 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose therapy (esomeprazole 40 mg, twice daily)
Number of subjects: 145
Study 25327949 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 29
Study 25327949 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 29
Study 23656302 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 378
Study 23656302 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 378
Study 23656302 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 378
Study 20737811 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable diacetylmorphine
Number of subjects: 60
Study 20737811 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 60
Study 18062784 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic decision support system
Number of subjects: 0
Study 18062784 — intervention group
Group type: COMPARATOR
Intervention: Paper documentation
Number of subjects: 0
Study 16009293 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiosk-based tailoring intervention (n = 70)
Number of subjects: 144
Study 12464464 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (400-1,000 mg/day)
Number of subjects: 309
Study 12464464 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (4-10 mg/day)
Number of subjects: 309
Study 10515677 — intervention group
Group type: EXPERIMENTAL
Intervention: 17betaE-D
Number of subjects: 121
Study 10515677 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE-N
Number of subjects: 121
Study 10515677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 8624228 — intervention group
Group type: EXPERIMENTAL
Intervention: Parodontax toothpaste
Number of subjects: 60
Study 8624228 — intervention group
Group type: COMPARATOR
Intervention: New toothpaste
Number of subjects: 60
Study 2290711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (Cef) 2 g daily infusion
Number of subjects: 44
Study 2290711 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) 2 g daily infusion
Number of subjects: 44
Study 6105713 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine combined with clorexolone
Number of subjects: 33
Study 6105713 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa combined with clorexolone
Number of subjects: 33
Study 6105713 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 33
Study 6105713 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 33
Study 31961463 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus megestrol acetate (MA) - MA (160 mg orally, daily) plus metformin (500 mg orally, three times a day)
Number of subjects: 150
Study 31961463 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate (MA) alone - MA (160 mg orally, daily)
Number of subjects: 150
Study 31961463 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus MA in AEH patients
Number of subjects: 150
Study 31961463 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus MA in non-obese AEH patients
Number of subjects: 150
Study 31961463 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus MA in insulin-sensitive AEH patients
Number of subjects: 150
Study 31831076 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive mobile messaging alert system
Number of subjects: 450
Study 31831076 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual antenatal care services)
Number of subjects: 450
Study 28231265 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT-based intervention
Number of subjects: 170
Study 28231265 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 170
Study 28231265 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 170
Study 25872747 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to site opening
Number of subjects: 322
Study 25872747 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to ethics and regulatory approval
Number of subjects: 322
Study 25872747 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to first randomisation
Number of subjects: 322
Study 25872747 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment rates
Number of subjects: 322
Study 25872747 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to electronic data collection (EDC)
Number of subjects: 322
Study 25872747 — intervention group
Group type: EXPERIMENTAL
Intervention: Time for initial SAE submission to sponsor
Number of subjects: 322
Study 25872747 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to submit final reports
Number of subjects: 322
Study 24225216 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT monitoring in guiding the use of antibiotics group (PCT group, n=42)
Number of subjects: 82
Study 24225216 — intervention group
Group type: COMPARATOR
Intervention: Regular antibiotic therapy group (RAT group, n=40)
Number of subjects: 82
Study 24225216 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PCT and RAT)
Number of subjects: 82
Study 21321243 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal plasma with elevated ratio of ApoCIII to ApoCII
Number of subjects: 311
Study 19692221 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 microg/day for 3 months followed by 100 microg/day for 9 months
Number of subjects: 57
Study 19692221 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 microg/day for 9 months
Number of subjects: 57
Study 19692221 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 microg/day for 3 months
Number of subjects: 57
Study 19692221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 17416150 — intervention group
Group type: EXPERIMENTAL
Intervention: ACBT with postural drainage (ACBT-PD)
Number of subjects: 36
Study 17416150 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cycle of breathing technique (ACBT)
Number of subjects: 36